AstraZeneca to stop development of olaparib for ovarian cancer
Tuesday, December 20 2011 | Comments
will not advance olaparib into Phase III development for the maintenance treatment of serous ovarian cancer.
The company made its decision after reviewing data from an interim analysis of a Phase II study of the drug. The study findings indicated that "the previously reported progression-free survival benefit is unlikely to translate into an overall survival benefit," which AstraZeneca described as the definitive measure of patient benefit in ovarian cancer.
Moreover, attempts to identify a suitable tablet dose for use in Phase III trials have not been successful, the company added. No new safety concerns were identified for patients who were treated with olaparib, an oral poly ADP-ribose polymerase inhibitor.
AstraZeneca said the firm would record a $285 million pretax charge as a result of its decision to terminate further development of olaparib in this indication.